Labcorp Holdings, Inc. Q4 FY2024 earnings call

Management Statement and Operational Highlights

• 2024 Strategic Execution: Closed or signed 10 transactions to partner with hospitals, health systems, and regional labs. Advanced in key growth markets like oncology and women's health. Acquired select assets of Invitae for genetic testing. Advanced Plasma Detect assay in 12 global trials. Launched Labcorp Global Trial Connect and Diagnostic Assistant.
• 2024 Financials: Revenue totaled $3.3 billion, up 10% year-over-year. Adjusted EPS was $3.45, up 5% year-over-year. Free cash flow from continuing operations was $665 million.
• 2025 Initiatives: Expect enterprise revenue growth of 6.7% to 8%, with adjusted EPS ranging from $15.60 to $16.40 and free cash flow $1.1 billion to $1.25 billion. Margins are expected to improve in both diagnostics and biopharma due to top-line growth and LaunchPad savings (aiming for $100 million to $125 million in annual savings).

Segment Performance

• Diagnostics Laboratories: Revenue in the quarter was $2.6 billion, an increase of 10.2% compared to the fourth quarter of 2023. Organic growth was 5.1% and net acquisitions contributed 5.2%. The base business was up 11.4% driven by organic growth of 6.2%. Total volume increased 6.8%, with base business volume growing 7.5%. Price/mix increased 3.4%. Adjusted operating income for the quarter was $360 million or 13.9% of revenue, down 120 basis points due to Invitae, weather, and days.
• Biopharma Laboratory Services: Revenue was $767 million, an increase of 10.4% compared to the fourth quarter of 2023. Organic revenue grew 8.9% and foreign currency translation contributed 1.5%. Central Labs revenue grew 10%, and Early Development had 12% year-over-year growth. Adjusted operating income was $131 million or 17% of revenue, up due to organic demand and LaunchPad savings, partially offset by higher personnel costs. The quarter ended with a backlog of $8 billion, with approximately $2.5 billion expected to convert to revenue over the next 12 months.

Guidance

• Enterprise revenue growth expected to be 6.7% to 8% in 2025.
• Diagnostics revenue growth projected at 6.5% to 7.7%, with half from organic growth and half from 2024 acquisitions. Biopharma revenue growth expected 3% to 5%.
• Adjusted EPS range $15.60 to $16.40, implying midpoint growth of 10%.
• Free cash flow guidance $1.1 billion to $1.25 billion, weighted towards the second half of the year.

Risks

• Impact of foreign exchange rates on revenue performance.
• Uncertainties related to regulatory changes (e.g., lab developed tests, PAMA) and their potential impact on operations and costs.
• Integration challenges with acquisitions, particularly in aligning systems and personnel.
• Weather and day-related fluctuations that can affect operational margins.

Question and Answer

Q: Michael Cherny asks about margins and the upside/downside of the EPS guidance.

A: Adam Schechter discusses that margins were impacted by Invitae, weather, and days, but expects margin expansion in 2025 as Invitae becomes slightly accretive, weather impact is built into guidance, and tailwinds from days help.

Q: Jack Meehan inquires about M&A pipeline and cash flow.

A: Adam Schechter and Julia Wang mention a strong M&A pipeline, active in hospital and regional lab deals, with capital allocation focused on dividends, accretive acquisitions, and buybacks. Leverage is manageable with balance sheet flexibility.

Q: Lisa Gill asks about organic growth in Diagnostics and lab developed tests lawsuit.

A: Adam Schechter talks about esoteric testing growth in specific areas at 3 times historical rates, and notes minimal financial impact from the lab developed tests lawsuit as most requirements were already met.

Q: Erin Wright asks about Biopharma market and NHP supply.

A: Adam Schechter and Julia Wang discuss Biopharma growth expectations, strong backlog in Central Labs, and stable early development with RFPs, win rates, and cancellations in line with normal levels.

Q: Andrew Brackmann asks about inflation and tariffs.

A: Adam Schechter mentions 3% to 3.5% inflation assumption and manageable tariff impact, with LaunchPad initiative helping offset labor cost increases.

Q: Pito Chickering asks about EV growth components and free cash flow conversion.

A: Julia Wang explains Biopharma growth comes from volume, with free cash flow guidance driven by higher cash earnings and working capital variability, targeting mid-80s cash conversion.